News

Nearly 6% of patients were waiting four hours or longer in A&D departments during the final quarter of 2012-13, which is the highest level since 2004, The King’s Fund has reported.

New late-stage data on Boehringer Ingelheim’s lung cancer drug nintedanib and its benefit to overall survival in some patients has caused a stir at the American Society of Clinical Oncology meeting in Chicago.

83% of US cancer doctors say they have faced oncology drug shortages and, of those, nearly all say that their patients’ treatment has been impacted, a new study reports.

Healthcare systems in the European Union (EU) are in urgent need of “shock-proofing” if they are to meet the challenges posed by severe pressure on budgets, a leading expert has warned.

GlaxoSmithKline has signed a licensing agreement worth up to €445.5 million euros ($577 million) for global rights to an experimental rheumatoid arthritis drug developed by German antibody specialist MorphoSys.

GlaxoSmithKline spin-off group Autifony Therapeutics has kicked off a Phase I trial of its experimental drug designed to tackle hearing disorders, with financial backing from Pfizer’s venture capital arm, among others.

The National Institute for Health and Care Excellence has published draft guidance which it hopes will help improve the diagnosis of serious bowel conditions.

Among the plethora of data being presented on melanoma treatments at the American Society of Clinical Oncology meeting in Chicago, Amgen has presented promising detailed late-stage data on talimogene laherparepvec, also known as T-Vec.

A new study has found that clinical trials for breast cancer are not including enough younger women, which could be affecting treatment outcomes.

The latest set of opinions from advisors to the European Medicines Agency sees seven new medicines recommended for approval.

Japanese group Fujifilm and India’s Dr Reddy’s have decided to break off plans to form an exclusive partnership to develop generic drugs for the Japanese market and establish a joint venture in the country.

The head of the NHS Confederation is warning that sticking plasters on ‘creaking parts of the NHS’ will soon fail, and only NHS leaders must “take up the gauntlet” and respond to the increasing pressures and challenges that lay ahead.

Sanofi has suffered a clinical setback and is pulling the plug on two late-stage drugs, iniparib for lung cancer and the anticoagulant otamixaban.

Shares in Sun Pharmaceutical Industries have fallen back on rumours it is in talks to buy Sweden’s Meda in the region of $5 billion.

Eli Lilly’s Strattera has become the first medicine in the UK to be approved specifically for treatment initiation in adults with attention-deficit hyperactivity disorder (ADHD).